For research use only. Not for therapeutic Use.
CCR1 antagonist 9 is a potent and selective CCR1 antagonist with an IC50 of 6.8 nM in calcium flux assay[1].
CCR1 antagonist 9 (Compound 19e) blocks the CCR1 chemotaxis of THP-1 cells with an IC50 of 28 nM. CCR1 antagonist 9 also blocks hERG with an IC50 of 30 μM[1].
| Catalog Number | I017409 |
| CAS Number | 1220026-26-5 |
| Synonyms | 1-(4-fluorophenyl)-N-[(2-methylsulfonylpyridin-4-yl)methyl]pyrazolo[3,4-c]pyridine-4-carboxamide |
| Molecular Formula | C20H16FN5O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C20H16FN5O3S/c1-30(28,29)19-8-13(6-7-23-19)9-24-20(27)17-10-22-12-18-16(17)11-25-26(18)15-4-2-14(21)3-5-15/h2-8,10-12H,9H2,1H3,(H,24,27) |
| InChIKey | DCHROQCNJDJPGN-UHFFFAOYSA-N |
| SMILES | CS(=O)(=O)C1=NC=CC(=C1)CNC(=O)C2=CN=CC3=C2C=NN3C4=CC=C(C=C4)F |
| Reference | [1]. Harcken C, et al. Identification of novel azaindazole CCR1 antagonist clinical candidates. Bioorg Med Chem Lett. 2019 Feb 1;29(3):441-448. |
